(Press-News.org) New York, NY, June 24, 2015 - The results of a study assessing safety and efficacy of sTMS therapy with the NEST® device in adult patients with Major Depressive Disorder (MDD) have been published in the Elsevier journal Brain Stimulation and are now available online on Science Direct.
In the study, over 200 subjects were analyzed across 17 leading academic and private psychiatric institutions in the United States; enrollment included both treatment naïve and treatment-resistant patients as prior exposure to antidepressant medication was not a requirement for inclusion into the trial.
"The study found sTMS therapy to be significantly more effective than sham when administered as intended, supporting the hypothesis that low-field magnetic stimulation improves depressive symptoms," said Principal Investigator Andrew Leuchter, MD, Professor of Psychiatry and Director of the Neuromodulation Division in the Semel Institute at UCLA1. "Additional analyses found subjects who failed to benefit from or tolerate prior antidepressant treatment in the current episode were most likely to demonstrate significant benefit from sTMS therapy compared to sham."
When delivered accurately and consistently, antidepressant resistant/intolerant subjects treated with active sTMS therapy achieved clinical response at a rate of 34.2% compared to 8.3% of those treated with an inactive device.
In addition, NEST® showed an attractive safety and tolerability profile, with no significant differences seen between active and sham treatment in the rate or severity of adverse events. There were no device-related serious adverse events in this study.
"These promising results indicate that sTMS is a promising novel technology for the treatment of depression," said co-author Mark S. George, MD, Distinguished Professor of Psychiatry, Radiology and Neurology at the Medical University of South Carolina, and the Editor-in-Chief of Brain Stimulation. "This technology is revolutionary in two ways over the current FDA-approved forms of TMS. First, this device tunes the stimulation to the patient's own brain rhythms. By stimulating at each patient's individual resonant frequency, sTMS may be able to achieve therapeutic success using lower energy. Second, this device is safe, easy to use, and portable, which would allow use in a wide variety of treatment settings. sTMS may expand the options we have for treating serious depression."
"We are very pleased with the outcome of this trial and what it could mean for those with MDD, particularly those who have failed to achieve adequate improvement from prior antidepressant treatment," said Kate Rumrill, President and CEO of NeoSync. "This study is an important milestone for the company on the path to bring sTMS to the market."
INFORMATION:
Notes for Editors
The article details of the study are: Leuchter AF, Cook IA, Feifel D, et al. Synchronized Transcranial Magnetic Stimulation (sTMS) Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Brain Stimulation 2015 http://dx.doi.org/10.1016/j.brs.2015.05.005
Article Information
1. Dr. Leuchter is also a stockholder of NeoSync and serves as their Medical Advisor.
Copies of study are available to credentialed journalists upon request.
About NEST® Technology
NEST® (NeoSync-EEG Synchronized TMS) delivers low energy, alternating magnetic field stimulation in daily 30 minute sessions (5 days/wk) to gently adjust a depressed patient's brain toward a more normal state. Unique among TMS therapies, the synchronized TMS (sTMS) used by NEST® is personalized to a patient's intrinsic alpha frequency (IAF), as measured by the electroencephalogram (EEG). This design theoretically allows therapeutic stimulation using lower magnetic field energy, providing greater patient comfort during stimulation. The lowered energy requirements also allow NEST® to be much smaller and more portable than traditional TMS systems. The FDA has classified the NEST system as a Non-Significant risk (NSR) medical device, currently for investigational use only.
About NeoSync, Inc.
NeoSync is a clinical-stage company with a proprietary platform technology being used to develop advanced, non-invasive neuromodulation products designed to treat Major Depressive Disorder and other diseases of the Central Nervous System (e.g. Autism, Parkinson's disease, Anxiety, Post-Traumatic Stress Disorder, etc.). The Company is led by experienced medical device executives and entrepreneurs. Headquartered in Newton, MA, NeoSync is privately held.
About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries. http://www.elsevier.com
Media contact
Natalie Hill-Krasniq
Brain Stimulation
n.hill-krasniqi@elsevier.com
Kate Rumrill
President and CEO
NeoSync
+1 781 373 1078
krumrill@neosync.com
Milan, Italy - 24 June 2015: The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today1 at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.2
The paper was produced by the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and is endorsed by the Heart Rhythm Society (HRS) in the US and the Asia Pacific Heart Rhythm Society (APHRS).
Professor Giuseppe Boriani, chair of the writing group, said: "CKD occurs in more than 10% of adults and has ...
Milan, Italy - 24 June 2015: A unique consensus paper on patient preferences for arrhythmias management is presented today1 at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.2
"Patients live with the consequences of treatments so it's reasonable that they should have some say."
The document was produced by the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and is endorsed by the Heart Rhythm Society (HRS) in the US, the Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación ...
Philadelphia, PA, June 24, 2015 - One American dies from suicide every 12.8 minutes, making suicide the tenth leading cause of death in the United States according to the American Foundation for Suicide Prevention. There is consensus that if we could better predict who was at risk for suicide, then we could more effectively intervene to reduce this terrible burden on individuals, families and public health.
A new analysis of existing studies strongly supports the idea that there are increased levels of chemicals, called cytokines, in the body and brain that promote inflammation ...
A University of Colorado Boulder scientist unexpectedly discovered two lichen species new to science in the same week while conducting research in Boulder Colorado, near the city's eastern limits.
After a day of fieldwork inventorying lichens at White Rocks Open Space, Erin Tripp was walking back to her car when an unfamiliar lichen caught her eye. Later that week, Tripp spotted a second species of lichen that she suspected might also be a new species.
Tripp, curator of botany for the University of Colorado Museum of Natural History and assistant professor of ecology ...
A study of how people can quickly spot animals by sight is helping uncover the workings of the human brain.
Scientists examined why volunteers who were shown hundreds of pictures - some with animals and some without - were able to detect animals in as little as one-tenth of a second.
They found that one of the first parts of the brain to process visual information - the primary visual cortex - can control this fast response, rather than more complex parts of the brain being required, as previously thought.
The findings suggest that when people look at a scene for ...
South African and Argentinian palaeontologists have discovered a new 200 million year old dinosaur from South Africa, and named it Sefapanosaurus, from the Sesotho word "sefapano".
The researchers from South Africa's University of Cape Town (UCT) and the University of the Witwatersrand (Wits University), and from the Argentinian Museo de La Plata and Museo Paleontológico Egidio Feruglio made the announcement in the scientific journal, Zoological Journal of the Linnaean Society. The paper, titled: A new basal sauropodiform from South Africa and the phylogenetic relationships ...
Boulder, Colo. -- The 26 December 2004 Mw ~9.2 Indian Ocean earthquake (also known as the Sumatra-Andaman or Aceh-Andaman earthquake), which generated massive, destructive tsunamis, especially along the Aceh coast of northern Sumatra, Indonesia, clearly demonstrated the need for a better understanding of how frequently subduction zone earthquakes and tsunamis occur. Toward that end, Harvey M. Kelsey of Humboldt State University and colleagues present a study of earthquake history in the area.
Using subsidence stratigraphy, the team traced the different modes of coastal ...
The tooth plate of just some millimeters in size had been in a box for more than 40 years, without being recognized after the discovery and preparation of the fish it belonged to. Palaeontologists from Naturalis Biodiversity Center, Netherlands and the University of Bristol, United Kingdom, studied the fossil using high energy X-rays at the Swiss Light Source at the Paul Scherrer Institut in Switzerland, revealing the structure and development of teeth and bones. Their findings are published today in Biology Letters.
Teeth are important in our daily life, they are crucial ...
A digital map of the ageing brain could aid the diagnosis of Alzheimer's disease and other neurodegenerative disorders in older people, a study suggests.
The atlas created using images from MRI scans of older people could aid diagnosis by comparing the patients' scans with a detailed map of the healthy ageing brain.
Most existing MRI atlases are based on the brains of young and middle-aged people, which don't reflect the normal changes that take place in the brain as we age, the team says.
Researchers at the University of Edinburgh constructed a detailed atlas of ...
Various diagnostic imaging techniques are currently used for clinical imaging/disease diagnosis. The accuracy of diagnosis is mainly based on the type of energy used (such as X-ray, sound waves, photons and positrons) to derive the visual information, as well as the degree of spatial resolution (mesoscopic or microscopic) and the level of information that can be obtained (physiological, anatomical or molecular). Based on potential health hazards imposed by type of energy used, clinical imaging modalities can be broadly categorized as ionizing and non-ionizing modalities. ...
